The Scripps collaboration is a positive platform validation event but lacks financial terms or near-term revenue catalysts. Monitor for follow-on grant awards or partnership announcements that could provide funded development milestones.
Price Chart
Executive Summary
Dyadic (DYAI) announced a research collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, using Dyadic's C1 microbial protein production platform. The collaboration builds on prior funded work with the Gates Foundation and CEPI, aims to leverage non-dilutive grants, and has no disclosed upfront payment or near-term revenue impact.
Key Facts
- Dyadic and Scripps Research collaborating on hantavirus (Andes virus) antibody and vaccine development
- Collaboration leverages Dyadic's C1 microbial platform for rapid, scalable biologic production
- No disclosed upfront payment, milestone payments, or funding commitment
- Parties plan to seek external non-dilutive funding (grants, sponsored research)
- Prior Andes virus mAb work showed neutralization comparable to ExpiCHO-produced material (preclinical)
- Dyadic is involved in other funded collaborations with Gates Foundation, CEPI, and FBS
- Commercial focus remains on non-pharmaceutical protein products and industrial biomanufacturing
Financial Impact
No disclosed financial terms, upfront payments, or funding commitments. Collaboration structured as grant-funded research with no dilution.
Risk Factors
- No funded commitment — collaboration is exploratory (evaluate potential) and depends on securing external grants
- Preclinical stage — hantavirus antibody/vaccine candidates are years from potential commercialization
- DYAI's primary commercial focus is non-pharmaceutical proteins; biopharma collaborations are validation but not core revenue drivers
- History of net losses and uncertain commercialization timeline for C1 platform
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025554 |
| Exhibit: ex99-1.htm | 0001493152-26-025554 |
| Document: 0001493152-26-025554-index-headers.html | 0001493152-26-025554 |
| Document: 0001493152-26-025554-index.html | 0001493152-26-025554 |
| Document: 0001493152-26-025554.txt | 0001493152-26-025554 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | SC 13G | $0.4194 | awaiting T+20 | — | $0.3900 (−7.01%) |
Sep 25, 2026 4w ago | 8-K | $0.4650 $0.4160 | ▲ +10.54% | ▲ +10.51% | $0.3900 (+16.13%) |
Sep 21, 2026 5w ago | EFFECT | $0.4010 $0.3809 | ▲ +5.01% | ▲ +4.10% | $0.3900 (+2.74%) |
Aug 14, 2026 10w ago | 8-K | $0.7751 $0.4244 | ▲ +45.25% | ▲ +43.25% | $0.3900 (+49.68%) |
Aug 12, 2026 10w ago | 8-K | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.3900 (+55.68%) |
Aug 12, 2026 10w ago | Press Release | $0.8800 $0.4898 | ▲ +44.34% | ▲ +42.44% | $0.3900 (+55.68%) |
Jul 24, 2026 13w ago | 8-K | $1.19 $0.6900 | ▼ −42.02% | ▼ −45.64% | $0.3900 (−67.23%) |
Jun 18, 2026 18w ago | DEFA14A | $0.7820 $1.19 | ▼ −52.17% | ▼ −51.64% | $0.3900 (+50.13%) |
May 28, 2026 21w ago | 8-K | $0.7100 $0.8010 | ▲ +12.82% | ▲ +15.96% | $0.3900 (−45.07%) |
Mar 25, 2026 30w ago | Press Release | $0.7000 $0.8600 | ▲ +22.86% | ▲ +12.19% | $0.3900 (−44.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers